Free webinar on single-cell research
Dolomite Bio, a provider of high-throughput single-cell technologies, has announced its latest webinar, titled ‘Getting started: Why should I use a Single Cell Consultancy Service?’
The webinar will explore the fundamentals for researchers taking their first steps into establishing a single-cell workflow in their lab and the role a single-cell consultancy service could play in getting started. It will be held on 11 August at 10 am CEST (6 pm AEST).
If you are new to the field, getting started in single-cell research can be daunting. The webinar will answer questions on the key frustrations that researchers experience, including concerns with capital cost investment, the uncertainty around whether a system is right for the research question or sample type (especially unusual cell types) and the expertise required to get the best results. The webinar will also cover how Dolomite Bio’s single-cell consultancy could benefit those simply looking to run a pilot study or a sample to complement a research paper.
Presenters include Dolomite Bio’s Dr Vincent Baron, Technical Applications Specialist and Dr Juliane Fischer, Content Manager. They will cover the following:
- Getting started with single-cell sequencing and the research questions it addresses
- Introduction to Dolomite Bio’s single-cell consultancy service
- Fast project delivery and the variety of sample types accepted
- The optimised workflow designed to work within budget and research needs
To register now, visit https://bit.ly/pr-scc-webinar.
Please follow us and share on Twitter and Facebook. You can also subscribe for FREE to our weekly newsletters and bimonthly magazine.
Curiox Biosystems sues BD and Waters for NDA breach
Curiox Biosystems has filed a lawsuit against BD and Waters Corporation for trade secret...
Australia signs Horizon Europe agreement in landmark deal
The agreement provides Australian researchers and organisations with access to Horizon Europe...
Suspicious citation numbers found in high-impact journals
The likely manipulation of citation numbers by research paper mills in high-impact cancer...
